PFE - Pfizer Inc Stock Price, Fair Value and News

25.38USD-0.04 (-0.16%)Market Closed

Market Summary

USD25.38-0.04

Market Closed

-0.16%

PFE Stock Price

View Fullscreen

PFE RSI Chart

PFE Valuation

Market Cap

143.5B

Price/Earnings (Trailing)

-103.34

Price/Sales (Trailing)

3.08

EV/EBITDA

21.19

Price/Free Cashflow

29.94

PFE Price/Sales (Trailing)

PFE Profitability

EBT Margin

2.27%

Return on Equity

-1.56%

Return on Assets

-0.61%

Free Cashflow Yield

3.34%

PFE Fundamentals

PFE Revenue

Revenue (TTM)

46.5B

Rev. Growth (Yr)

703.37%

Rev. Growth (Qtr)

97.99%

PFE Earnings

Earnings (TTM)

-1.4B

Earnings Growth (Yr)

-34.36%

Earnings Growth (Qtr)

105.81%

Breaking Down PFE Revenue

Last 7 days

-3.5%

Last 30 days

-8.3%

Last 90 days

-9.5%

Trailing 12 Months

-37.3%

How does PFE drawdown profile look like?

PFE Financial Health

Current Ratio

0.91

Debt/Equity

0.7

Debt/Cashflow

0.14

PFE Investor Care

Dividend Yield

6.49%

Dividend/Share (TTM)

1.65

Shares Dilution (1Y)

0.49%

Diluted EPS (TTM)

0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	32.7B	33.0B	23.6B	46.5B
2022	49.9B	34.2B	32.8B	32.6B
2021	46.1B	55.1B	68.9B	60.9B
2020	37.9B	34.5B	32.1B	41.7B
2019	41.0B	40.8B	40.2B	40.9B
2018	52.7B	53.2B	53.4B	40.8B
2017	52.6B	52.3B	52.5B	52.5B
2016	51.0B	52.3B	53.2B	52.8B
2015	49.1B	48.2B	47.9B	48.9B
2014	50.5B	50.3B	50.0B	49.6B
2013	52.7B	51.7B	51.4B	51.6B
2012	59.7B	57.1B	53.5B	55.2B
2011	65.1B	64.4B	65.1B	61.3B
2010	55.0B	61.1B	65.5B	65.2B
2009	47.3B	46.2B	45.8B	49.3B
2008	0	48.4B	48.3B	48.3B
2007	0	0	0	48.4B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Pfizer Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 28, 2024	boshoff christoffel	sold (taxes)	-112,216	27.04	-4,150	executive vice president
Feb 28, 2024	dolsten mikael	sold (taxes)	-579,656	27.04	-21,437	president r&d
Feb 28, 2024	boshoff christoffel	acquired	-	-	11,510	executive vice president
Feb 27, 2024	damico jennifer b.	acquired	-	-	5,113	svp & controller
Feb 27, 2024	de germay alexandre	acquired	-	-	74,377	executive vice president
Feb 26, 2024	mcdermott michael	sold (taxes)	-164,792	27.18	-6,063	executive vice president
Feb 25, 2024	boshoff christoffel	sold (taxes)	-172,029	27.76	-6,197	executive vice president
Feb 25, 2024	boshoff christoffel	acquired	-	-	15,455	executive vice president
Feb 25, 2024	mcdermott michael	sold (taxes)	-83,057	27.76	-2,992	executive vice president
Feb 25, 2024	damico jennifer b.	sold (taxes)	-38,475	27.76	-1,386	svp & controller

Which funds bought or sold PFE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	Financial Management Professionals, Inc.	added	11.7	38,000	530,000	0.08%
Apr 16, 2024	Indiana Trust & Investment Management CO	added	2.42	-6,095	469,919	0.19%
Apr 16, 2024	HENGEHOLD CAPITAL MANAGEMENT LLC	added	24.04	527,850	3,227,000	0.34%
Apr 16, 2024	Sawyer & Company, Inc	added	2.38	-8,129	577,871	0.23%
Apr 16, 2024	Independence Bank of Kentucky	reduced	-13.13	-321,730	1,655,510	0.50%
Apr 16, 2024	FLAGSHIP HARBOR ADVISORS, LLC	added	17.42	215,382	1,849,910	0.12%
Apr 16, 2024	Stratos Wealth Partners, LTD.	added	16.53	795,019	7,249,130	0.12%
Apr 16, 2024	R.H. Dinel Investment Counsel, Inc.	unchanged	-	-73,746	1,967,750	1.26%
Apr 16, 2024	Chesley Taft & Associates LLC	reduced	-2.72	-278,912	4,196,520	0.22%
Apr 16, 2024	Lincoln Capital LLC	unchanged	-	-13,062	348,512	0.08%

Are Funds Buying or Selling PFE?

Are funds buying PFE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PFE

No. of Funds

Unveiling Pfizer Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.97%	506,479,807	SC 13G/A
Jan 29, 2024	state street corp	5.10%	287,875,814	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	434,748,255	SC 13G/A
Feb 09, 2023	vanguard group inc	8.94%	501,636,220	SC 13G/A
Feb 07, 2023	state street corp	5.08%	284,943,697	SC 13G/A
Feb 03, 2023	blackrock inc.	7.9%	442,868,761	SC 13G/A
Feb 14, 2022	state street corp	5.09%	285,771,591	SC 13G/A
Feb 10, 2022	vanguard group inc	8.29%	465,274,925	SC 13G/A
Feb 01, 2022	blackrock inc.	7.3%	409,985,645	SC 13G/A
Feb 12, 2021	state street corp	5.03%	279,831,373	SC 13G

Recent SEC filings of Pfizer Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	PX14A6G	PX14A6G
Apr 11, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 11, 2024	DEFA14A	DEFA14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 09, 2024	DEFA14A	DEFA14A
Apr 01, 2024	4	Insider Trading

Peers (Alternatives to Pfizer Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	348.8B	85.2B	-7.62%	-10.06%	9.92	4.1	6.46%	95.94%
MRK	317.6B	60.1B	3.25%	9.20%	870.05	5.28	1.40%	-97.49%
PFE	143.5B	46.5B	-8.33%	-37.34%	-103.34	3.08	42.59%	-114.62%
AMGN	141.5B	28.2B	-2.53%	7.29%	21.07	5.02	7.09%	2.52%
GILD	83.4B	27.1B	-8.60%	-20.08%	14.73	3.08	-0.60%	23.36%
TEVA	14.8B	15.8B	-0.90%	54.57%	-25.67	0.93	6.17%	76.47%
MID-CAP
PRGO	4.1B	4.7B	0.13%	-17.24%	-320.54	0.87	4.58%	90.97%
ALKS	4.0B	1.7B	-12.75%	-17.88%	11.28	2.41	49.61%	324.78%
BHC	3.2B	8.8B	-7.68%	16.09%	-5.35	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-6.53%	-6.23%	14	2.99	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-10.42%	-30.36%	-3.78	1.79	24.65%	80.36%
TXMD	21.8M	1.3M	-17.83%	-48.08%	-2.12	16.74	-98.14%	-109.18%
ACRX	17.1M	-	-12.17%	23.93%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.5M	19.6M	-33.93%	-94.71%	-0.18	0.13	80.00%	43.08%
ACOR	422.3K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

Pfizer Inc News

Latest updates

Pfizer Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	98.0%	26,198	13,232	3,490	3,627	3,261	22,638	3,219	3,526	3,420	24,035	18,899	14,516	11,427	10,277	9,864	10,083	1,843	12,680	13,264	13,118	1,155
S&GA Expenses	39.4%	4,575	3,281	3,497	3,418	4,645	3,391	3,048	2,593	4,104	2,899	2,923	2,777	3,739	2,658	2,659	2,541	2,616	3,260	3,511	3,339	2,164
EBITDA Margin	-	0.21*	-	0.89*	1.17*	1.26*	1.22*	1.13*	0.69*	0.51*	0.43*	0.40*	0.40*	-	-	-	-	-	-	-	-	-
Interest Expenses	219.9%	1,062	332	402	419	321	350	318	453	262	407	353	445	344	387	438	472	341	437	424	385	343
Income Taxes	17.5%	-795	-964	-71.00	715	230	356	1,570	1,172	249	-328	1,123	808	-64.00	-347	422	359	-1,982	3,047	-915	433	-1,536
Earnings Before Taxes	-23.2%	-4,129	-3,352	2,269	6,270	5,231	9,001	11,447	9,050	3,827	7,843	6,949	5,692	598	570	3,026	2,842	-7,869	10,727	4,141	4,323	-9,237
EBT Margin	-94.8%	0.02*	0.44*	0.69*	0.98*	1.06*	1.02*	0.94*	0.55*	0.40*	0.31*	0.25*	-	-	-	-	-	-	-	-	-	-
Net Income	105.8%	139	-2,382	382	473	211	8,608	210	468	578	8,146	330	461	221	1,469	518	405	37.00	148	5,046	3,884	-393
Net Income Margin	46.5%	-0.03*	-0.06*	0.29*	0.29*	0.29*	0.30*	0.27*	0.19*	0.16*	0.13*	0.05*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	58.6%	4,196	2,646	-2,122	73.00	7,581	5,133	7,419	5,898	4,912	10,211	10,762	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	428.8%	226,501	42,830	220,168	196,000	197,000	41,137	195,290	183,841	181,476	46,335	169,920	158,818	154,229	44,975	44,244	45,840	167,594	46,081	156,199	155,000	159,000
Current Assets	637.5%	43,333	5,876	73,347	50,078	51,259	5,932	67,466	54,420	59,693	6,890	48,814	39,533	35,067	6,614	7,136	8,213	32,803	7,505	47,073	45,290	49,926
Cash Equivalents	-9.4%	2,853	3,148	2,632	2,166	416	1,338	1,824	2,513	1,983	2,034	2,418	1,809	1,825	1,627	1,845	2,196	1,350	2,846	1,837	2,018	1,225
Inventory	-0.1%	10,189	10,204	10,310	9,541	8,981	9,513	10,454	9,979	9,059	8,640	8,948	8,493	8,020	9,295	8,564	8,423	7,068	8,222	8,233	8,029	7,508
Net PPE	6.0%	18,940	17,862	17,488	17,052	16,274	15,441	15,244	15,109	14,882	14,436	14,224	14,011	13,745	14,403	14,113	14,040	12,969	13,701	13,521	13,467	13,385
Goodwill	31.5%	67,783	51,527	51,572	51,476	51,375	823	49,891	50,211	49,208	49,489	49,867	49,791	49,556	59,902	58,449	58,502	48,181	58,665	53,352	53,487	42,927
Liabilities	527.6%	137,213	21,862	120,875	94,381	101,288	22,455	107,821	101,155	104,013	10,351	99,605	89,953	90,756	10,576	10,187	10,677	104,148	10,776	96,274	96,263	95,664
Current Liabilities	681.3%	47,794	6,117	34,647	36,562	42,138	5,235	47,410	39,268	42,671	5,133	35,664	26,652	25,920	5,246	4,992	5,524	37,304	5,241	32,030	29,423	31,858
Long Term Debt	1.6%	62,000	61,048	61,356	31,704	32,884	32,629	34,294	35,656	36,000	36,250	35,354	35,347	37,000	49,785	50,529	36,281	35,955	36,044	36,168	35,733	32,909
LT Debt, Current	-0.3%	2,254	2,260	3,565	3,567	2,560	2,566	1,276	260	1,636	2,663	3,687	3,676	2,002	2,149	1,481	337	1,462	2,431	2,139	4,471	4,776
LT Debt, Non Current	1.6%	62,000	61,048	61,356	31,704	32,884	32,629	34,294	35,656	36,000	36,250	35,354	35,347	37,000	49,785	50,529	36,281	35,955	36,044	36,168	35,733	32,909
Shareholder's Equity	329.6%	89,014	20,719	99,293	101,236	95,661	18,455	87,469	82,685	77,462	35,705	70,315	68,865	63,473	34,154	64,570	65,341	63,447	35,199	59,924	59,158	63,758
Retained Earnings	-6.4%	118,353	126,411	128,796	131,102	125,656	122,967	116,608	111,193	103,394	102,252	96,346	95,158	90,392	100,284	100,203	101,000	97,670	100,113	94,440	93,388	89,554
Additional Paid-In Capital	0.1%	92,631	92,496	92,329	92,153	91,802	91,359	91,183	90,844	90,591	89,973	89,336	89,002	88,674	88,161	87,886	87,680	87,428	87,099	86,963	86,635	86,253
Accumulated Depreciation	-100.0%	-	15,779	15,554	15,514	15,174	14,931	14,969	15,358	15,074	15,403	15,328	15,105	14,812	16,636	16,889	16,929	16,789	16,728	16,389	16,158	16,591
Shares Outstanding	-0.1%	5,643	5,646	5,640	5,634	5,608	5,606	5,605	5,617	5,601	5,597	5,598	-	-	-	-	-	-	-	-	-	-
Minority Interest	10.0%	274	249	274	266	256	227	261	261	262	279	273	245	235	245	138	133	303	105	357	352	351
Float	-	-	-	207,000	-	-	-	294,000	-	-	-	223,000	-	-	-	169,000	-	-	-	241,000	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	51.6%	5,240	3,456	-1,208	1,212	8,582	5,974	8,170	6,541	5,914	10,829	11,299	4,538	5,625	2,090	3,555	3,133	3,769	4,510	2,611	1,698	4,738
Share Based Compensation	-19.9%	121	151	148	105	364	135	287	86.00	496	293	221	172	287	224	187	57.00	239	64.00	199	185	241
Cashflow From Investing	-1338.3%	-10,996	888	-25,485	3,315	-4,410	-627	-11,313	567	-2,586	-10,076	-8,137	-1,747	8,330	481	-13,011	-71.00	-2,833	-6,760	-1,902	7,550	-764
Cashflow From Financing	244.0%	5,442	-3,779	27,174	-2,771	-5,015	-5,761	2,520	-6,578	-3,351	-1,101	-2,557	-2,807	-13,787	-2,821	9,159	-2,200	-2,440	3,273	-851	-8,467	-6,407
Buy Backs	-	-	-	-	-	-	-	-	2,000	-	-	-	-	-	-	-	-	-	-	-	8,865	5,030

PFE Income Statement

2023-12-31

Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Income Statement [Abstract]

Product revenues

^[1]

$ 50,914

$ 91,793

$ 73,636

Alliance revenues

^[1]

7,582

8,537

7,652

Total revenues

^[2]

58,496

100,330

81,288

Costs and expenses:

Cost of sales

^[3],[4]

24,954

34,344

30,821

Selling, informational and administrative expenses

^[3]

14,771

13,677

12,703

Research and development expenses

^[3]

10,679

11,428

10,360

Acquired in-process research and development expenses

194

953

3,469

Amortization of intangible assets

4,733

3,609

3,700

Restructuring charges and certain acquisition-related costs

2,943

1,375

802

Other (income)/deductions––net

(835)

217

(4,878)

Income from continuing operations before provision/(benefit) for taxes on income

^[2],[5],[6]

1,058

34,729

24,311

Provision/(benefit) for taxes on income

(1,115)

3,328

1,852

Income from continuing operations

2,172

31,401

22,459

Discontinued operations––net of tax

(15)

(434)

Net income before allocation to noncontrolling interests

2,158

31,407

22,025

Less: Net income attributable to noncontrolling interests

Net income attributable to Pfizer Inc. common shareholders

$ 2,119

$ 31,372

$ 21,979

Earnings per common share––basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

$ 0.38

$ 5.59

$ 4.00

Discontinued operations––net of tax (in dollars per share)

(0.08)

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

0.38

5.59

3.92

Earnings per common share––diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

0.37

5.47

3.93

Discontinued operations––net of tax (in dollars per share)

(0.08)

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

$ 0.37

$ 5.47

$ 3.85

Weighted-average shares––basic

5,643

5,608

5,601

Weighted-average shares––diluted

5,709

5,733

5,708

[1]	See Note 1G.
[2]	Earnings = Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s revenues and earnings in 2023 reflect a non-cash revenue reversal of $3.5 billion (see Note 17C). Biopharma’s earnings also include dividend income from our investment in ViiV of $265 million in 2023, $314 million in 2022 and $166 million in 2021.
[3]	Exclusive of amortization of intangible assets.
[4]	See Notes 8A and 17A.
[5]	2022 v. 2021––The decrease in domestic income is primarily related to net losses on equity securities in 2022 versus net gains on equity securities in 2021, lower net periodic benefit credits and higher restructuring charges and certain acquisition-related costs, partially offset by Paxlovid income and lower acquired IPR&D expenses. The increase in international income is primarily related to Paxlovid and Comirnaty income partially offset by lower net periodic benefit credits.
[6]	2023 v. 2022––The domestic loss in 2023 versus domestic income in 2022 and the decrease in international income in 2023 was primarily attributable to lower revenues, higher intangible asset impairment charges, and increases in Restructuring charges and certain acquisition-related costs, Amortization of intangible assets, and Selling, informational and administrative expenses, partially offset by a decrease in Cost of sales and net gains on equity securities in 2023 versus net losses on equity securities in 2022.

PFE Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)
$ in Millions

Dec. 31, 2023

Dec. 31, 2022

Assets

Cash and cash equivalents

$ 2,853

$ 416

Short-term investments

9,837

22,316

Trade accounts receivable, less allowance for doubtful accounts: 2023—$470; 2022—$449

11,177

10,952

Inventories

^[1]

10,189

8,981

Current tax assets

3,978

3,577

Other current assets

5,299

5,017

Total current assets

43,333

51,259

Equity-method investments

11,637

11,033

Long-term investments

3,731

4,036

Property, plant and equipment

18,940

16,274

Identifiable intangible assets

^[2]

64,900

43,370

Goodwill

^[3]

67,783

51,375

Noncurrent deferred tax assets and other noncurrent tax assets

3,706

6,693

Other noncurrent assets

12,471

13,163

Total assets

226,501

197,205

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2023—$2,254; 2022—$2,560

10,350

2,945

Trade accounts payable

6,710

6,809

Dividends payable

2,372

2,303

Income taxes payable

2,349

1,587

Accrued compensation and related items

2,776

3,407

Deferred revenues

2,700

2,520

Other current liabilities

20,537

22,568

Total current liabilities

47,794

42,138

Long-term debt

61,538

32,884

Pension and postretirement benefit obligations

2,167

2,250

Noncurrent deferred tax liabilities

640

1,023

Other taxes payable

8,534

9,812

Other noncurrent liabilities

16,539

13,180

Total liabilities

137,213

101,288

Commitments and Contingencies

Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding as of December 31, 2023 and December 31, 2022

Common stock, $0.05 par value; 12,000 shares authorized; issued: 2023—9,562; 2022—9,519

478

476

Additional paid-in capital

92,631

91,802

Treasury stock, shares at cost: 2023—3,916; 2022—3,903

(114,487)

(113,969)

Retained earnings

118,353

125,656

Accumulated other comprehensive loss

(7,961)

(8,304)

Total Pfizer Inc. shareholders’ equity

89,014

95,661

Equity attributable to noncontrolling interests

274

256

Total equity

89,288

95,916

Total liabilities and equity

$ 226,501

$ 197,205

[1]	The increase from December 31, 2022 of $1.2 billion reflects an increase of approximately $1.0 billion representing acquired Seagen inventory, inclusive of the fair value step-up (see Note 2A), and increases for certain products due to new product launches, supply recovery and changes in net market demand. These increases were offset to a large extent by $1.0 billion in inventory write-offs for Paxlovid and Comirnaty.
[2]	The increase is primarily due to $28.8 billion for the acquisition of Seagen (see Note 2A) and the $495 million of capitalized milestones described in note (a) above, partially offset by amortization expense of $4.7 billion and impairments of $3.0 billion (see Note 4).
[3]	Our goodwill balance continues to be assigned within the Biopharma reportable segment.

About Pfizer Inc

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

CEO	Dr. Albert Bourla D.V.M., DVM, Ph.D.
WEBSITE	pfizer.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	65535

Pfizer Inc Frequently Asked Questions

What is the ticker symbol for Pfizer Inc? What does PFE stand for in stocks?

PFE is the stock ticker symbol of Pfizer Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pfizer Inc (PFE)?

As of Wed Apr 17 2024, market cap of Pfizer Inc is 143.48 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PFE stock?

You can check PFE's fair value in chart for subscribers.

What is the fair value of PFE stock?

You can check PFE's fair value in chart for subscribers. The fair value of Pfizer Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pfizer Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PFE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pfizer Inc a good stock to buy?

The fair value guage provides a quick view whether PFE is over valued or under valued. Whether Pfizer Inc is cheap or expensive depends on the assumptions which impact Pfizer Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PFE.

What is Pfizer Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, PFE's PE ratio (Price to Earnings) is -103.34 and Price to Sales (PS) ratio is 3.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PFE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pfizer Inc's stock?

In the past 10 years, Pfizer Inc has provided 0.014 (multiply by 100 for percentage) rate of return.